iCell Gene Therapeutics

CAR-T cell therapy (private)

Privately held: no public share price · United States

Assets

(4 total)
4Total Assets
0Approved
0Phase 3 / Filed
4Phase 1–2 / Early
4Diseases
Quick filter:
Showing 4 of 4 assets
Target & Modality
Phase 2
BCMA / CD19Cell therapy
Inflammatory Bowel DiseaseSystemic Lupus Erythematosus
Ulcerative Colitis, Crohn's Disease
Anti-CD33 CAR T-cellsNo recent activity
Phase 1
CD33Cell therapy
Acute Myeloid Leukemia
Phase 1
BCMA / CD19Cell therapy
Multiple MyelomaSystemic Lupus Erythematosus
Phase 1
CD33; CLL1 (CLEC12A)Cell therapy
Acute Myeloid Leukemia

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2028 (2)
April 2028 (1)
ICG318Phase 1/2Inflammatory Bowel Diseases (IBD)
Est. primary completion 2028-04-07 · NCT07544160 · CT.gov ↗
What to watch
December 2028 (1)
ICG318Phase 2Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN)
Est. primary completion 2028-12 · NCT07328581 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

No financial reports recorded.